Tomatsuri Naoya, Yoshida Norimasa, Takagi Tomohisa, Katada Kazuhiro, Isozaki Yutaka, Imamoto Eiko, Uchiyama Kazuhiko, Kokura Satoshi, Ichikawa Hiroshi, Naito Yuji, Okanoue Takeshi, Yoshikawa Toshikazu
Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Int J Mol Med. 2004 Jan;13(1):105-9.
Although edaravone (3-methyl-1-phenyl-pyrazolin-5-one), a newly developed radical scavenging agent, has been widely used for protection against ischemia-reperfusion (I-R) injury in patients with cerebral infarction, its effects on gastrointestinal I-R injury have not been evaluated. In the present study, we examined the effects of edaravone on experimental intestinal I-R damage in rats. In male Wistar rats with and without edaravone treatment, intestinal damage was induced by clamping the superior mesenteric artery for 30 min, followed by reperfusion. Edaravone was administered via intravenous infusion at 5 min before reperfusion was achieved by removal of the clamp. The rats were sacrificed after 60 min of reperfusion. Luminal protein and hemoglobin concentrations were measured as an index of mucosal injury and histological examination of hematoxylin and eosin-stained sections was performed. Thiobarbituric acid (TBA)-reactive substances and tissue-associated myeloperoxidase (MPO) activity were measured in the mucosa as indicators of lipid peroxidation and neutrophil infiltration, respectively. The mucosal concentration of cytokine-induced neutrophil chemoattractant (CINC)-1 (a member of the IL-8 family) was determined by enzyme-linked immunosorbent assay (ELISA). Additionally, CINC-1 messenger RNA (mRNA) was measured by the reverse-transcription polymerase chain reaction (RT-PCR). As a result, the levels of luminal protein and hemoglobin, TBA-reactive substances, and MPO activity were all increased significantly by I-R injury, and these increases were significantly inhibited by treatment with edaravone. Multiple erosions and bleeding were observed macroscopically after the small intestine was exposed to I-R injury, and these changes were inhibited by administration of edaravone. Microscopic I-R damage was also reduced by treatment with edaravone. CINC-1 protein and CINC-1 mRNA were both increased by I-R injury, while edaravone markedly reduced the levels of both protein and mRNA. In summary, these results suggest that edaravone can protect the small intestine against I-R injury by scavenging oxygen-derived free radicals.
依达拉奉(3-甲基-1-苯基-吡唑啉-5-酮)是一种新开发的自由基清除剂,已被广泛用于保护脑梗死患者免受缺血再灌注(I-R)损伤,但其对胃肠道I-R损伤的影响尚未得到评估。在本研究中,我们检测了依达拉奉对大鼠实验性肠I-R损伤的影响。在有或没有依达拉奉治疗的雄性Wistar大鼠中,通过夹闭肠系膜上动脉30分钟诱导肠损伤,然后再灌注。在通过移除夹子实现再灌注前5分钟,通过静脉输注给予依达拉奉。再灌注60分钟后处死大鼠。测量肠腔蛋白和血红蛋白浓度作为黏膜损伤的指标,并对苏木精和伊红染色切片进行组织学检查。在黏膜中分别测量硫代巴比妥酸(TBA)反应性物质和组织相关髓过氧化物酶(MPO)活性,作为脂质过氧化和中性粒细胞浸润的指标。通过酶联免疫吸附测定(ELISA)测定细胞因子诱导的中性粒细胞趋化因子(CINC)-1(IL-8家族成员)的黏膜浓度。此外,通过逆转录聚合酶链反应(RT-PCR)测量CINC-1信使核糖核酸(mRNA)。结果,I-R损伤显著增加了肠腔蛋白和血红蛋白水平、TBA反应性物质以及MPO活性,而依达拉奉治疗显著抑制了这些增加。小肠暴露于I-R损伤后,肉眼观察到多处糜烂和出血,而给予依达拉奉可抑制这些变化。依达拉奉治疗也减少了微观I-R损伤。I-R损伤使CINC-1蛋白和CINC-1 mRNA均增加,而依达拉奉显著降低了蛋白和mRNA水平。总之,这些结果表明依达拉奉可通过清除氧衍生的自由基保护小肠免受I-R损伤。